Supernus Pharmaceuticals Stock (NASDAQ: SUPN)

Dernières nouvelles pour Supernus Pharmaceuticals (NASDAQ:SUPN) Stock

SUPERNUS PHARMACEUTICALS INC

Supernus Pharmaceuticals

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Supernus Pharmaceuticals, Inc. - Common Stock

Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) on Monday agreed to acquire Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) for $12.00 per share in cash, or an aggregate of up to approximately $795 million.
The deal consideration includes $8.50 per share in cash (or an aggregate of approximately $561 million) plus one non-tradable contingent value right (CVR) collectively worth up to $3.50 per share in cash (or an aggregate of approximately $234 million).
"This acquisition represents a major step in bolstering our future growth. It augments our growth profile by adding a significant fourth growth product to our portfolio and further diversifies our sources of future growth. Zurzuvae aligns with our focus of acquiring novel value-enhancing and clinically differentiated medicines to treat CNS conditions," said Jack Khattar, president and CEO of Supernus Pharmaceuticals.
Sage Therapeutics shares gained 0.4% to trade at $9.11 on Tuesday.
These analysts made changes to their price targets on Sage Therapeutics following acquisition announcement.
<ul class="wp-block-list">
<li>Canaccord Genuity analyst Sumant Kulkarni maintained Sage Therapeutics with a Hold and raised the price target from $8 to $8.5.</li>
<li>Truist Securities analyst Joon Lee maintained the stock with a Hold and raised the price target from $8 to $9.</li>
<li>Piper Sandler analyst David Amsellem downgraded Sage Therapeutics from Overweight to Neutral and lowered the price target from $9 to $8.5.</li>
</ul>
Considering buying SAGE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/SAGE/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="574" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17142045/image-267-1024x574.png" alt="" class="wp-image-952816" style="width:612px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17142045/image-267-1024x574.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17142045/image-267-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17142045/image-267-768x430.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17142045/image-267.png 1137w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/45973780/nvidia-to-rally-more-than-38-here-are-10-top-analyst-forecasts-for-tuesday">Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday</a> </li>
</ul>
Photo via Shutterstock

News

Price Target

Markets

Analyst Ratings

Trading Ideas

SAGE

SUPN

These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News

Supernus Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) on Monday agreed to acquire Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) for $12.00 per share in cash, or an aggregate of up to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45945434/supernus-pharmaceuticals-to-acquire-sage-therapeutics-strengthening-its-neuropsychiatry-product-po" rel="noreferrer noopener">approximately $795 million</a>.
The deal consideration includes $8.50 per share in cash (or an aggregate of approximately $561 million) plus one non-tradable contingent value right (CVR) collectively worth up to $3.50 per share in cash (or an aggregate of approximately $234 million).
The CVR is payable upon achieving certain net sales and commercial milestones. The transaction is expected to close in the third quarter of 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43815436/supernus-pharmaceuticals-stock-falls-on-disappointing-data-from-treatment-resistant-depression-trial" rel="noreferrer noopener">Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial</a>
<h2 class="wp-block-heading">Strategic and Financial Benefits</h2>
The acquisition significantly strengthens Supernus Pharmaceuticals&#8217; psychiatry portfolio by adding Zurzuvae (zuranolone) capsules CIV, a landmark drug that stands as the first and only oral medicine approved by the FDA for treating postpartum depression in adults.
This strategic addition is set to diversify and substantially increase Supernus Pharmaceuticals&#8217; revenue base and cash flow. The financial impact is already evident from the collaboration revenue derived from Zurzuvae&#8217;s net sales, which, representing 50% of the net revenue recorded by Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), amounted to $36.1 million for the full year 2024 and $13.8 million in the first quarter of 2025 alone.
Supernus believes that with Zurzuvae joining its three other key growth products, Qelbree, ONAPGO, and GOCOVRI, the company is poised for significant future growth.
Beyond the immediate commercial benefits, the deal also augments Supernus Pharmaceuticals&#8217; central nervous system (CNS) discovery platforms and deepens its expertise in the field.
Furthermore, the strong integration potential with Supernus Pharmaceuticals&#8217; existing infrastructure is expected to yield substantial operational efficiencies, with projected annual cost synergies of up to $200 million.
&#8220;This acquisition represents a major step in bolstering our future growth. It augments our growth profile by adding a significant fourth growth product to our portfolio and further diversifies our sources of future growth. Zurzuvae aligns with our focus of acquiring novel value-enhancing and clinically differentiated medicines to treat CNS conditions,&#8221; said Jack Khattar, president and CEO of Supernus Pharmaceuticals.
In a significant development <a href="https://www.benzinga.com//node/42957657">preceding the acquisition</a> by Supernus Pharmaceuticals, Biogen Inc. had made an unsolicited, non-binding proposal to acquire all of the outstanding shares of Sage Therapeutics that it did not already own. The offer was made on January 10, 2025, for a price of $7.22 per share.
In October 2024, Sage Therapeutics announced a strategic reorganization of its business operations to support the ongoing launch of Zurzuvae (zuranolone)&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41376682/sage-therapeutics-announces-strategic-reorganization-to-prioritize-zurzuvae-commercialization-and-" rel="noreferrer noopener">in postpartum depression</a>.
The company said the reorganization was intended to strengthen Sage&#8217;s balance sheet, extend its cash runway, and position the company for long-term growth potential.
The company&#8217;s layoff impacted over 165 employees (approximately 33% of its total workforce and approximately 55% of its R&amp;D workforce), including changes to&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41382549/after-series-of-trial-setbacks-sage-therapeutics-to-lay-off-one-third-workforce" rel="noreferrer noopener">the leadership team</a>.
In September 2024, Biogen terminated its rights under the collaboration and license agreement with Sage, which was specific to the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41049022/biogen-terminates-collaboration-with-sage-therapeutics-for-neurological-disorder-candidate" rel="noreferrer noopener">SAGE-324 program</a>.
Price Action: SAGE stock was trading higher by 36.3% to $9.13 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/03/44190052/johnson-johnson-stops-late-stage-depression-study-over-insufficient-efficacy" target="_blank" rel="noreferrer noopener">Johnson &amp; Johnson Stops Late-Stage Depression Study Over &#8216;Insufficient Efficacy&#8217;</a></li>
</ul>
Photo Courtesy: S Prodution on Shutterstock.com

Biotech

Health Care

Movers

General

BIIB

Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal

<ul>
<li>Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.</li>
<li>Strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE&#xAE; (zuranolone), and a novel CNS discovery platform.</li>
<li>Expected to be significantly accretive in 2026 with potential cost synergies of up to $200 million on an annual basis.</li>
<li>Upfront cash payment of $8.50 per share, plus one non-tradable contingent value right (CVR) payable upon achieving certain specific milestones collectively worth up to $3.50 per share in cash, for an aggregate of up to approximately $795 million or $12.00 per share.</li>
</ul>

Supernus Pharmaceuticals Agrees To Buy Sage Therapeutics For $8.50/Share Plus One Contingent Value Right Worth Up To $3.50 Per Share In Cash, For Total Consideration Of $12/Share

Supernus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) affirms FY2025 sales outlook from $600.00 million-$630.00 million to $600.00 million-$630.00 million vs $624.69 million estimate.

Guidance

Supernus Pharmaceuticals Affirms FY2025 Sales Guidance of $600.00M-$630.00M vs $624.69M Est

Supernus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) reported quarterly losses of $(0.21) per share. The company reported quarterly sales of $149.824 million which beat the analyst consensus estimate of $146.936 million by 1.97 percent. This is a 4.30 percent increase over sales of $143.644 million the same period last year.

Earnings

Earnings Beats

Supernus Pharmaceuticals Q1 2025 GAAP EPS $(0.21), Sales $149.824M Beat $146.936M Estimate

ACLS

AHCO

ALAB

ALGS

ALGT

AMTM

ANDE

ANET

ANGI

ARDT

ARIS

ARMK

ARQT

ARRY

ATKR

ATOM

ATRO

AUDC

AVNS

AVNT

AVNW

AZEK

BALL

BBNX

BCAB

BLDP

BRLT

BWIN

BWMN

CCCS

CCLD

CDRE

CELH

CGAU

CGBD

CHMI

CHRD

CIFR

CIGI

CLDT

CLOV

COTY

CPAY

CPIX

CPNG

CRCT

CRIS

CRMD

CRSR

CRUS

CURI

CVGI

CXDO

CYTK

DASH

DAWN

DDOG

DOCN

DRCT

DRVN

DVAX

ENLT

EOSE

Embraer-Empresa Brasileira De Aeronautica

ESPR

EVGO

Earnings Scheduled For May 6, 2025

Supernus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-06. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Supernus Pharmaceuticals will report an earnings per share (EPS) of $0.39.
Supernus Pharmaceuticals bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
The company's EPS missed by $0.25 in the last quarter, leading to a 2.74% drop in the share price on the following day.
Here's a look at Supernus Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.52</td>
<td>0.44</td>
<td>0.39</td>
<td>0.38</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.27</td>
<td>0.69</td>
<td>0.36</td>
<td>0</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>0.0%</td>
<td>14.000000000000002%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746464507_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Supernus Pharmaceuticals were trading at $32.84 as of May 02. Over the last 52-week period, shares are up 4.62%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on Supernus Pharmaceuticals</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Supernus Pharmaceuticals.
With 2 analyst ratings, Supernus Pharmaceuticals has a consensus rating of Neutral. The average one-year price target is $36.0, indicating a potential 9.62% upside.
<h3>Analyzing Ratings Among Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of Harmony Biosciences Hldgs and Tarsus Pharmaceuticals, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Harmony Biosciences Hldgs, with an average 1-year price target of $54.5, suggesting a potential 65.96% upside.</li>
<li>Analysts currently favor an Buy trajectory for Tarsus Pharmaceuticals, with an average 1-year price target of $67.33, suggesting a potential 105.02% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
In the peer analysis summary, key metrics for Harmony Biosciences Hldgs and Tarsus Pharmaceuticals are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supernus Pharmaceuticals</td>
<td>Neutral</td>
<td>5.99%</td>
<td>$148.06M</td>
<td>1.50%</td>
</tr>
<tr>
<td>Harmony Biosciences Hldgs</td>
<td>Buy</td>
<td>19.51%</td>
<td>$146.86M</td>
<td>7.88%</td>
</tr>
<tr>
<td>Tarsus Pharmaceuticals</td>
<td>Buy</td>
<td>183.68%</td>
<td>$73.12M</td>
<td>-8.86%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Supernus Pharmaceuticals ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.
<h3>About Supernus Pharmaceuticals</h3>
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
<h3>Supernus Pharmaceuticals's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Supernus Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 5.99% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 8.8%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Supernus Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.5% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Supernus Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.13%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.03, Supernus Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/SUPN/earnings">To track all earnings releases for Supernus Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Uncovering Potential: Supernus Pharmaceuticals's Earnings Preview

Cantor Fitzgerald analyst Kristen Kluska reiterates Supernus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) with a Neutral and maintains $36 price target.

Reiteration

Cantor Fitzgerald Reiterates Neutral on Supernus Pharmaceuticals, Maintains $36 Price Target

Supernus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) sees FY2025 sales of $600.000 million-$630.000 million vs $622.18 million analyst estimate.

Supernus Pharmaceuticals Sees FY2025 Sales $600.000M-$630.000M vs $622.18M Est

Supernus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) reported quarterly earnings of $0.27 per share which missed the analyst consensus estimate of $0.52 by 48.08 percent. This is a 30.77 percent decrease over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $174.16 million which beat the analyst consensus estimate of $155.25 million by 12.18 percent. This is a 5.99 percent increase over sales of $164.31 million the same period last year.

Earnings Misses

Supernus Pharmaceuticals Q4 EPS $0.27 Misses $0.52 Estimate, Sales $174.16M Beat $155.25M Estimate

ALLT

AXGN

AXON

BASE

BGFV

BLZE

BTDR

CART

CAVA

CBLL

CECO

CPSS

DNUT

ELAN

EXLS

FIHL

FLYW

FSLR

FULC

GPOR

HRMY

HSIC

HURN

HYLN

IART

ICCC

IGIC

IMOS

INGN

INTU

INVX

IPAR

ITRI

IVAC

JACK

JAZZ

KEYS

KNSA

LCID

LGIH

LIVN

LMND

LXFR

MASI

MATX

MFIC

MIDD

MMSI

MPLN

MRVI

NOVT

NXRT

Earnings Scheduled For February 25, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Catherine Schulte downgraded the rating for Qiagen N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) from Outperform to Neutral and lowered the price target from $52 to $42. Qiagen shares closed at $40.01 on Tuesday. <a href="https://www.benzinga.com/quote/QGEN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Catherine Schulte downgraded Bio-Techne Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) from Outperform to Neutral and lowered the price target from $88 to $68. Bio-Techne shares closed at $65.29 on Tuesday. <a href="https://www.benzinga.com/quote/TECH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Keith Weiss downgraded Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) from Overweight to Equal-Weight and lowered the price target from $330 to $275. Workday shares closed at $265.72 on Tuesday. <a href="https://www.benzinga.com/quote/WDAY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B. Riley Securities analyst Kyle Bauser downgraded the rating for Tactile Systems Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) from Buy to Neutral and slashed the price target from $23 to $18. Tactile Systems shares closed at $17.86 on Tuesday. <a href="https://www.benzinga.com/quote/TCMD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald analyst Kristen Kluska downgraded Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) from Overweight to Neutral and lowered the price target from $57 to $36. Supernus Pharmaceuticals shares closed at $39.75 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying WDAY stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="427" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19084320/image-168-1024x427.png" alt="" class="wp-image-788949" style="width:460px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19084320/image-168-1024x427.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19084320/image-168-300x125.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19084320/image-168-768x320.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19084320/image-168.png 1527w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43776863/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter-3">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

Downgrades

Pre-Market Outlook

CRVO

QGEN

TCMD

TECH

WDAY

This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

On Tuesday, Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) revealed the topline data from the Phase 2b study of SPN-820 in adults with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43798052/supernus-announces-topline-results-from-phase-2b-study-in-adults-with-treatment-resistant-depressi" rel="noreferrer noopener">treatment-resistant depression (TRD)</a>.
The study did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score to Week 4, a widely used clinician‐rated measure of depressive severity.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40820529/adhd-drug-maker-supernus-pharmaceuticals-downgraded-on-slower-prescription-growth-f" rel="noreferrer noopener">ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug</a>
There was no treatment difference between SPN-820 and placebo in the change from baseline to Week 4 for the secondary endpoints.
The safety profile of SPN-820 was consistent with previous clinical trials, showing few adverse events.
&#8220;We are disappointed that the trial did not meet its primary endpoint in this patient population,&#8221; said Jack Khattar, President and CEO of Supernus. &#8220;We will continue to analyze these data and discuss the future of the program with our development partner, Navitor Pharmaceuticals.&#8221;
In October, Supernus Pharmaceuticals revealed data from its exploratory open-label Phase 2a clinical study of SPN-820 in adults with <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41390811/supernus-announces-promising-data-from-open-label-phase-2a-study-of-spn-820-in-adults-with-major-d" rel="noreferrer noopener">major depressive disorder</a>.
Phase 2a study demonstrated a rapid and substantial decrease in depressive symptoms. SPN-820 was well-tolerated with few adverse events.
Earlier this month, the FDA approved&nbsp;Supernus Pharmaceuticals&#8217; ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for motor fluctuations in adults with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43462326/supernus-announces-fda-approval-of-onapgo-apomorphine-hydrochloride-for-parkinsons-disease" rel="noreferrer noopener">advanced Parkinson&#8217;s disease</a>.
Supernus will make ONAPGO available in the second quarter of 2025.
Price Action: SUPN stock is down 14.10% at $34.20 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/asset-sales/25/02/43811409/nikola-files-for-bankruptcy-seeks-auction-for-sale-of-its-assets" target="_blank" rel="noreferrer noopener">Nikola Files For Bankruptcy, Seeks Auction For Sale Of Its Assets</a></li>
</ul>
Photo via Shutterstock

Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial

WIIM

Supernus Pharmaceuticals shares are trading lower after Cantor Fitzgerald downgraded the stock from Overweight to Neutral and cut its price target from $57 to $36.

Cantor Fitzgerald analyst Kristen Kluska downgrades Supernus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) from Overweight to Neutral and lowers the price target from $57 to $36.

Cantor Fitzgerald Downgrades Supernus Pharmaceuticals to Neutral, Lowers Price Target to $36

U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Wednesday.
Shares of Gentherm Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/quote/THRM/news">weak quarterly results.</a>
Gentherm shares dipped 17% to $30.00 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) fell 22% to $31.00 in pre-market trading after the company announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale.</li>
<li>InnovAge Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) fell 21.1% to $2.70 in today's pre-market trading. InnovAge recently reported worse-than-expected second-quarter financial results.</li>
<li>Bumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) declined 17.3% to $6.70 in pre-market trading after the company issued first-quarter revenue guidance below estimates and announced a quarter-over-quarter decline in paying app users.</li>
<li>GCL Global Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCL#NASDAQ">GCL</a>) fell 14.7% to $6.40 in pre-market trading after jumping 153% on Tuesday.</li>
<li>Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) shares dipped 13.5% to $60.50 in pre-market trading after the company issued first-quarter EPS guidance below estimates.</li>
<li>Koninklijke Philips N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) declined 11.9% to $24.94 in pre-market trading following weak quarterly results.</li>
<li>Solaris Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLSR#NYSE">SLSR</a>) fell 7.7% to $3.60 in pre-market trading.</li>
<li>Etsy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) declined 6.8% to $53.35 in pre-market trading after reporting a 6.8% YoY decline in fourth-quarter GMV and guiding for a similar YoY GMV decline in the first quarter.</li>
<li>Toll Brothers, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) fell 5.4% to $115.50 in pre-market trading after the company reported worse-than-expected first-quarter financial results..</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43776863/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter-3">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

BMBL

ETSY

INNV

SLSR

THRM

Gentherm Posts Downbeat Results, Joins Celanese, Bumble And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Shares of Global Blue Group Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GB#NYSE">GB</a>) rose sharply during Wednesday's pre-market trading session after the company announced it will be acquired by Shift4 for <a href="https://www.benzinga.com/quote/gb/analyst-ratings">$7.50 per share</a>.
Global Blue Group shares jumped 18.3% to $7.37 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Cycurion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCU#NASDAQ">CYCU</a>) rose 132.5% to $7.79 in pre-market trading after dipping 72% on Tuesday.</li>
<li>OSR Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) shares jumped 96.4% to $6.11 in pre-market trading after gaining 3% on Tuesday.</li>
<li>Lytus Technologies Holdings PTV. Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYT#NASDAQ">LYT</a>) gained 52.7% to $0.34 in pre-market trading after dipping 14% on Tuesday.</li>
<li>ReShape Lifesciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) gained 43.3% to $1.55 in pre-market trading. ReShape Lifesciences shares dipped around 54% on Tuesday after the company announced a $6 million public offering of 2,575,107 units at $2.33 per unit.</li>
<li>Sintx Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares climbed 38.3% to $3.90 in pre-market trading. Sintx Technologies announced the issuance of U.S. patent no. 12,239,761 by the United States Patent and Trademark Office.</li>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) gained 35.2% to $2.96 in pre-market trading after gaining around 12% on Tuesday.</li>
<li>TruGolf Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>) gained 33.1% to $0.5444 in pre-market trading after the company guided 2024 sales of $22.5 million and 2H adjusted EBITDA above $2.2 million.</li>
<li>Aditxt, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) gained 22.3% to $0.1345 in pre-market after surging 57% on Tuesday.</li>
<li>Mercurity Fintech Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>) rose 14.5% to $8.00. MFH&#8217;s majority-owned subsidiary Aifinity Base Limited plans to manufacture advanced liquid cooling solutions for Nvidia&#xAE; chip-powered AI data centers and high-performance computing.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Movano Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOVE#NASDAQ">MOVE</a>) shares fell 36.4% to $3.25 in pre-market trading.</li>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) shares fell 25.5% to $0.1439 in pre-market trading after gaining around 8% on Tuesday.</li>
<li>Design Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) dipped 24.5% to $3.120 in pre-market trading.</li>
<li>Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) fell 22% to $31.00 in pre-market trading after the company announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale.</li>
<li>InnovAge Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) fell 21.1% to $2.70 in today's pre-market trading. InnovAge recently reported worse-than-expected second-quarter financial results.</li>
<li>MGO Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) shares tumbled 20.9% to $0.3680 in pre-market trading after dipping 35% on Tuesday. MGO Global&#8217;s stockholders approved business combination with Heidmar.</li>
<li>Bumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) declined 17.3% to $6.70 in pre-market trading after the company issued first-quarter revenue guidance below estimates and announced a quarter-over-quarter decline in paying app users.</li>
<li>Gentherm Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) fell 17% to $30.00 in pre-market trading following weak quarterly results.</li>
<li>Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) shares dipped 13.5% to $60.50 in pre-market trading after the company issued first-quarter EPS guidance below estimates.</li>
<li>Nexa Resources S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEXA#NYSE">NEXA</a>) fell 10.6% to $4.60 in pre-market trading following a 7% decline on Tuesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43776863/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter-3">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

ADTX

APTO

CYCU

DSGN

MGOL

MOVE

NEXA

NIVF

OSRH

RSLS

SINT

TRUG

Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

Supernus Pharmaceuticals shares are trading lower after the company announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale.

SPN-820 was well-tolerated with few adverse events, consistent with previously reported studies.

Supernus Reports Results From Phase 2b Study In Adults With Treatment Resistant Depression; Study Did Not Show Statistically Significant Improvement On Primary Endpoint Of Reduction In Depressive Symptoms

Comments

Supernus Pharmaceuticals

Actualités

Dernières nouvelles pour Supernus Pharmaceuticals (NASDAQ:SUPN) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL